SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is drawing significant attention as the community eagerly anticipates pivotal Phase 3 data for its GPS cancer immunotherapy, with CEO comments on potential curative outcomes driving strong speculation of a massive short squeeze. Investors are actively dismissing bearish takes, instead focusing on shattered technical resistance and accumulation signals that point to a major market revaluation or buyout.

"What's Updog?" is a Community Led token.

UpDog

UPDOG CRYPTO is trending as its dedicated community celebrates its two-year anniversary on the Solana blockchain, driving conversation around the iconic "Whats UpDog?" meme and maintaining a bullish "The Dog Stays Up" sentiment with calls to accumulate.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is rallying as market sentiment interprets recent statements on the Mideast conflict as a sign of de-escalation, sparking a 'Trump pump' and optimistic price targets among bulls, while skeptics warn of market manipulation, rising oil prices, and continued geopolitical uncertainty.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is a hot topic after its recent earnings showed a beat on Q4 results but presented a cautious outlook for the coming fiscal year, fueling mixed sentiment. While many in the community are debating short squeeze potential and highlighting the company's substantial real estate assets, others are concerned about soft sales trends and the broader challenging retail landscape.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is actively discussed following its proposed convertible senior notes offering, which raises community questions about management's strategy amid persistent buyout rumors and growing optimism for Casgevy's commercial ramp-up and positive early data from its zugo-cel program, including a new Eli Lilly partnership.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending as its co-founders establish a new mRNA innovations company and Pfizer reportedly sells its stake, fueling community debate over the company's strategic pivot to its robust oncology pipeline, backed by significant cash reserves, amidst broader market skepticism about mRNA technology.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing intense community debate ahead of its earnings report, as investors weigh significant debt-fueled AI infrastructure spending and recent layoff rumors against its cloud growth potential, further complicated by conflicting reports surrounding a major OpenAI data center project.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is actively discussed following an analyst upgrade highlighting strong demand for its upcoming R2, which is set for a highly anticipated unveiling on March 12. This event is fueling community excitement and debate over its transformative potential and pricing amidst rising oil costs.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending as its recent earnings and management commentary highlight balance sheet stability, positive free cash flow, and international growth, leading to strong community discussion about its significant undervaluation and AI leadership within the expanding telehealth sector.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is trending due to its aggressive investments in U.S. connectivity, fiber, and AI infrastructure, coupled with a strong earnings report, positive long-term outlook, and a substantial share buyback program. The community is actively debating whether these strategic moves position it as a compelling value and dividend play, despite ongoing competitive pressures in the telecom sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026 Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026 PR Newswire REHOVOT, Israel, March 9...

Evogene Earnings Review: Q4 Summary

Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

Evogene Reports Fourth Quarter and Full Year 2025 Financial Results Evogene Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire REHOVOT, Israel, March 5, 2026 Conference call and...

Evogene Releases CEO Letter to Shareholders

Evogene Releases CEO Letter to Shareholders Evogene Releases CEO Letter to Shareholders PR Newswire REHOVOT, Israel, Feb. 25, 2026 Updating on Strategic Progress and OutlookREHOVOT, Israel, Feb. 25...

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release PR Newswire REHOVOT, Israel, Feb. 19, 2026...

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

Current Price	$0.7649
Prev Close	$0.7677
Open	$0.7768
Dividend Yield	0.00%
50-Day Moving Average	$0.9912
Beta	0.83
Avg. Volume	1.3M
PE Ratio	-1.56

52-Week High	$2.42
52-Week Low	$0.73
Market Capitalization	$6.67M
EPS (Annual)	-$2.89
Price to Book	5.84
Revenue Per Employee	$72,743.59

EVGN
Evogene Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EVGN News

EVGNEvogene Ltd